白细胞介素-1阻滞剂在心血管疾病中的研究进展  

Research progress of interleukin-1 blockers in cardiovascular diseases

作　　者：蒋小眉 谭华清 秧茂盛[1] 唐湘宇[1,2] JIANG Xiao-mei;TAN Hua-qing;YANG Mao-sheng;TANG Xiang-yu(Jishou University School of Medicine,Hu′nan Province,Jishou 416000,China;The Eighteenth Ward,Department of Cardiology,Loudi Central Hospital,Hu′nan Province,Loudi 417000,China)

机构地区：[1]吉首大学医学院,湖南吉首416000 [2]湖南省娄底市中心医院心血管内科18病室,湖南娄底417000

出　　处：《中国当代医药》2019年第35期17-21,共5页China Modern Medicine

基　　金：湖南省临床医疗技术创新引导项目(2017SK51209)

摘　　要：白细胞介素-1作为先天免疫系统的关键细胞因子在心血管疾病中的作用逐渐显现。阻断白细胞介素-1已被证明在其他心血管疾病中有效,如心肌炎、心律失常和心力衰竭。本综述旨在总结白细胞介素-1阻滞剂在心血管疾病中的作用,简要描述其发病机理及相关的临床研究。阻断白细胞介素-1通路可能是一种新的治疗策略,可能成为许多急慢性心血管疾病的治疗方法。Interleukin-1, as a key cytokine of innate immune system, is playing an increasingly important role in cardiovascular diseases. Blocking interleukin-1 has proved to be effective in other cardiovascular diseases, such as myocarditis, arrhythmia, and heart failure. This review aims to summarize the role of interleukin-1 blockers in cardiovascular disease, and briefly describe its pathogenesis and related clinical studies. Blocking the interleukin-1 pathway may be a new therapeutic strategy and may become a treatment for many acute and chronic cardiovascular diseases.

关 键 词：白细胞介素-1 阿那白滞素 卡那单抗 心包炎 动脉粥样硬化 心血管疾病 

分 类 号：R543.3[医药卫生—心血管疾病]